Thread: NORTHERA™ (droxidopa) Phase III, Chelsea Therapeutics Inter
View Single Post
Old 02-08-2011, 08:03 PM
CarolynS CarolynS is offline
Member
  
Join Date: Nov 2008
Location: Corning NY
Posts: 304
15 yr Member
CarolynS CarolynS is offline
Member
 
Join Date: Nov 2008
Location: Corning NY
Posts: 304
15 yr Member
Default NORTHERA™ (droxidopa) Phase III, Chelsea Therapeutics Inter
Chelsea Therapeutics Announces Interim Results and Plans to Modify Study 306 to Focus on Reduction in Falls Associated With Neurogenic Orthostatic Hypotension

CHARLOTTE, N.C., — Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announces plans to modify Study 306, a Phase III study of NORTHERA™ (droxidopa) in symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson’s disease (PD) following a futility determination at the planned interim analysis of the study’s primary endpoint and an unblinded review of multiple, secondary outcome measures showing dramatic reduction in falls and clear signs of therapeutic activity associated with Northera in the first 51 patients to complete Study 306.
CarolynS is offline   Reply With QuoteReply With Quote